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Use of plasma renin activity to monitor mineralocorticoid substitution in dogs with 
primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone. 
 
Die Plasmareninaktivität (PRA) gilt als Goldstandard zur Therapiekontrolle der 
Mineralokortikoidsubstitution bei Menschen mit primärem Hypoadrenokortizismus 
(HA). Ziele der Arbeit waren der Vergleich der PRA bei Hunden mit neu 
diagnostiziertem HA, Hunden mit HA ähnlichem Krankheitsbild und gesunden 
Hunden, sowie die Evaluation der PRA bei Hunden mit HA unter 
Fludrocortisonacetat (FC) oder Desoxycorticosteronpivalat (DOCP). Die PRA wurde 
bei 11 Hunden mit neu diagnostiziertem HA (Gruppe 1), 10 Hunden mit HA 
ähnlichem Krankheitsbild (Gruppe 2), 21 gesunden Hunden (Gruppe 3) und 17 
bereits behandelten Hunden mit HA (Gruppe 4) gemessen. In Gruppe 1 wurde die 
PRA vor Behandlung und zu verschiedenen Zeitpunkten nach Therapiestart, in 
Gruppe 2 und 3 nur bei Erstvorstellung gemessen. In Gruppe 4 wurde kein Basalwert 
der PRA bestimmt, die PRA wurde jedoch ein- oder mehrmals alle 1 bis 6 Monate 
unter Therapie bestimmt. Die PRA vor Therapie war bei Hunden mit HA im Vergleich 
zu normalen Hunden oder Hunden mit HA ähnlichem Krankheitsbild erhöht. Unter 
Therapie sank die PRA bei Hunden mit HA und normalisierte sich mit DOCP, nicht 
jedoch mit FC. Bei mit DOCP behandelten Hunden war die PRA tiefer als bei mit FC 
behandelten Hunden. Die Natriumkonzentration war höher und die 
Kaliumkonzentration tiefer unter Therapie mit DOCP verglichen mit FC. Die PRA ist 
ein zuverlässiger Parameter zur Kontrolle der Mineralokortikoidsubstitution. DOCP 
erniedrigt die PRA bei Hunden mit HA effektiver als FC. 
 
Schlüsselwörter: Nebenniereninsuffizienz; Hunde; Renin; 
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Use of plasma renin activity to monitor mineralocorticoid substitution in dogs with 
primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone. 
 
Measurement of plasma renin activity (PRA) is the gold standard for monitoring 
mineralocorticoid substitution in humans with primary hypoadrenocorticism (PH). 
Objectives were to compare PRA in dogs with newly diagnosed PH, dogs with 
diseases mimicking PH and healthy dogs and to evaluate measurement of PRA to 
monitor fludrocortisone acetate (FC) or desoxycorticosterone pivalate (DOCP) 
treatment in dogs with PH. PRA was measured in 11 dogs with newly diagnosed PH 
(group 1), 10 dogs with diseases mimicking PH (group 2), 21 healthy dogs (group 3) 
and 17 dogs with PH already treated for PH (group 4).  In group 1, PRA was 
measured before treatment and at different times after initiating therapy. In groups 2 
and 3, PRA was measured at initial presentation only. In group 4, no baseline PRA 
was obtained but PRA was measured once or repeatedly every 1 to 6 months during 
therapy.  PRA before therapy was increased in dogs with PH compared to normal 
dogs and dogs with diseases mimicking PH with median activity of 27, 0.8 and 1.0 
ng/ml/h, respectively. In dogs with PH, PRA decreased and normalized under 
mineralocorticoid substitution with DOCP but not with FC. In dogs on DOCP, PRA 
was lower than in dogs on FC. At the same time, plasma sodium concentrations were 
higher and potassium lower on DOCP compared to FC treatment. PRA is a reliable 
tool for monitoring mineralocorticoid substitution. DOCP treatment more effectively 
suppresses PRA compared to FC therapy in dogs with PH.  
 
Key words: adrenal insufficiency; canine; renin; 
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Abstract 
Background: Measurement of plasma renin activity (PRA) is the gold standard for 
monitoring mineralocorticoid treatment in humans with primary hypoadrenocorticism 
(PH).  
Objectives: To compare PRA in dogs with newly diagnosed PH, dogs with diseases 
mimicking PH and healthy dogs and evaluate measurement of PRA to monitor 
therapeutic effects in dogs with PH treated with different mineralocorticoids.  
Animals: 11 dogs with newly diagnosed PH (group 1), 10 dogs with diseases 
mimicking PH (group 2), 21 healthy dogs (group 3), 17 dogs with treated PH (group 
4).  
Methods: In group 1, PRA was measured before treatment and at different times 
after initiating therapy. In groups 2 and 3, PRA was measured at initial presentation 
only. In group 4, no baseline PRA was obtained but PRA was measured once or 
every 1 to 6 months during therapy. Mineralocorticoid treatment consisted of 
fludrocortisone acetate (FC) or desoxycorticosterone pivalate (DOCP). 
Results: PRA before therapy was increased in dogs with PH compared to normal 
dogs and dogs with diseases mimicking PH with median activity of 27, 0.8 and 1.0 
ng/ml/h, respectively. In dogs with PH, PRA decreased and normalized with 
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mineralocorticoid treatment using DOCP but not with FC. In dogs treated with DOCP, 
PRA was lower than in dogs treated with FC. Plasma sodium concentrations were 
higher and potassium concentrations were lower with DOCP treatment compared to 
FC treatment.  
Conclusion and Clinical Importance: PRA is a reliable tool for monitoring 
mineralocorticoid treatment. DOCP treatment more effectively suppresses PRA 
compared to FC in dogs with PH.  
 
Most dogs with primary hypoadrenocorticism (PH) suffer from immune-mediated 
destruction of the adrenal cortex, which results in absolute glucocorticoid and 
mineralocorticoid deficiency. Due to negative feedback, high concentrations of 
endogenous ACTH accompany glucocorticoid deficiency. Similarly, lack of 
aldosterone in patients with PH is accompanied by high concentrations of plasma 
angiotensin II that can be estimated indirectly by species-specific renin 
concentrations or by plasma renin activity (i.e. angiotensin generated by a plasma 
sample during timed incubation).1  
Treatment for PH consists of life-long hormone replacement.2 Mineralocorticoids 
usually are replaced by either fludrocortisone acetate (FC) or desoxycorticosterone 
pivalate (DOCP). Fludrocortisone acetate administered PO is the most commonly 
used treatment for humans with PH and has been recommended for dogs with PH for 
many years.3 Fludrocortisone possesses potent mineralocorticoid activity and some 
glucocorticoid activity. Thus, in some cases there is no need for additional 
glucocorticoid supplementation. Signs of glucocorticoid overdosage can, however, 
occur, even when serum electrolyte concentrations still are not well controlled.4  
 7 
Desoxycorticosterone pivalate is a parenterally administered long-acting 
mineralocorticoid alternative. Desoxycorticosterone pivalate has no glucocorticoid 
activity, and additional supplementation with glucocorticoids is recommended in all 
cases. The choice of mineralocorticoid replacement is based on several factors such 
as product availability, cost of treatment and personal preference of  the clinician and 
client.3,5 Reports on the effectiveness and monitoring of mineralocorticoid therapy in 
dogs with PH are limited. Several authors report that DOCP is superior to FC, 
whereas in 1 large comparative clinical study no difference was seen with regard to 
survival time and control of serum electrolyte concentrations.3-6 The most important 
causes of poor response to treatment in dogs with PH are an inadequate 
mineralocorticoid dose or serious adverse glucocorticoid effects. Furthermore, the 
expense of mineralocorticoid supplementation may cause some owners to consider 
euthanasia.7 In human medicine, standard monitoring of patients with PH consists of 
measurement of serum electrolyte concentrations, blood pressure and plasma renin 
activity (PRA). Plasma renin activity determination to control mineralocorticoid 
therapy was first described in 1975 and had been accepted as the gold standard 
since 1992.8-11 Plasma renin activity before treatment is increased in humans with PH 
and it decreases during therapy and correlates inversely with mineralocorticoid dose. 
Therefore, a target range for PRA is defined for optimal treatment in humans.10  
In dogs with newly diagnosed PH, PRA is significantly higher than that in normal 
dogs.1 The role of PRA in monitoring mineralocorticoid therapy in dogs with PH has 
not been investigated. Mineralocorticoid treatment currently is monitored mainly by 
serum potassium and sodium concentrations. The objectives of our study were, first, 
to measure and compare PRA in newly diagnosed PH dogs, in dogs with diseases 
mimicking PH and in healthy dogs and, second, to evaluate PRA in dogs with PH 
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during mineralocorticoid therapy. We hypothesized that PRA in dogs with PH would 
be significantly higher than that in dogs with diseases mimicking PH or in healthy 
dogs, that PRA would decrease during mineralocorticoid treatment and that it would 
be lower in well-controlled dogs than in poorly controlled dogs.  
 
Material and Methods 
 
Animals 
Group 1: Eleven client-owned dogs with newly-diagnosed PH were prospectively 
enrolled between January 2011 and August 2013. One of these dogs had been part 
of a previous study.12 Diagnostic evaluation included CBC, serum biochemical profile, 
urinalysis, ACTH stimulation test, measurement of endogenous plasma ACTH 
concentration and abdominal ultrasonography (with particular attention to the adrenal 
glands) in all dogs. PH was confirmed if serum cortisol concentrations after synthetic 
ACTH administration did not increase adequately (< 1 μg/dl) and if endogenous 
baseline plasma ACTH concentrations were increased (cACTH > 130 pmol/l). Dogs 
were enrolled in the study if their serum sodium concentration was < 152 mmol/l, 
their serum potassium concentration was > 5.3 mmol/l or both. Dogs with normal 
electrolyte concentrations and dogs with iatrogenic PH (i.e., previous corticosteroid or 
trilostane therapy) were excluded from the study.  
Group 2: Ten dogs with diseases mimicking PH diagnosed between June 2010 and 
February 2012 were prospectively enrolled in the study. All dogs initially had been 
suspected of having PH but finally were determined to have a different disease; all 
had post-ACTH serum cortisol concentrations ≥ 4.5 μg/dl. Diseases mimicking PH 
were associated with clinical signs, laboratory findings or both routinely seen in dogs 
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with PH, such as vomiting, diarrhea, weakness, lethargy, hyperkalemia, 
hyponatremia, or some combination of these.  
Group 3: Twenty-one privately-owned dogs were used as controls. The dogs were 
considered to be healthy on the basis of normal history and physical examination, as 
well as unremarkable hematology and serum biochemistry profile results. 
Group 4: Seventeen client-owned dogs with PH that had already been treated for PH 
were prospectively enrolled between June 2010 and July 2013. PH had been 
diagnosed between 2 weeks and 7 years previously based on typical electrolyte 
abnormalities and an inadequate post-ACTH serum cortisol concentration (< 1 μg/dl). 
All of these dogs were being treated with mineralocorticoid and glucocorticoid 
supplementation at the time of inclusion into the study.  
All procedures were approved by the Cantonal Veterinary Office of Zurich 
(permission number, TVB 72/2011) and conducted in accordance with guidelines 
established by the Animal Welfare Act of Switzerland. In addition, informed consent 
was obtained from the owners of the healthy dogs. 
 
Analytical procedures 
For the ACTH simulation test, blood samples were collected before and 60 min after 
IV injection of 250 µg synthetic ACTHa. Cortisol concentrations were measured by 
chemiluminescence assay.b The sensitivity of the cortisol assay was 0.2 µg/dl. 
Endogenous plasma ACTH concentration before ACTH stimulation was determined 
by a chemiluminescence assay.b  Blood for cACTH determination was collected into 
chilled EDTA-coated tubes placed on ice and centrifuged at 4°C. Cortisol and cACTH 
measurements were performed in-house twice a week; plasma was stored either at -
20°C (cortisol) or at -80°C (ACTH) until assayed. 
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PRA was measured with an enzymatic assay in the Division of Angiology and 
Hypertension, Department of Medicine, Lausanne University Hospital, Lausanne, 
Switzerland. The method is based on trapping of angiotensin I generated in plasma 
during incubation at 37°C and subsequent radioimmunoassay.13 The detection limit 
was 0.025 ng AngI/ml/h. The within- and between-assay precisions were 
characterized by coefficients of variation of 5.1% and 13.0%, respectively. The 
reference values (5 and 95% percentiles) for healthy dogs were 0.1 – 1.7 ng 
AngI/ml/h and were virtually identical to human normal values (0.05 – 2.4 ng 
AngI/ml/h) and they were (unlike in human subjects) independent of the postprandial 
time.14  Blood was collected into chilled EDTA-coated tubes, placed on ice and 
centrifuged immediately at 4°C. Plasma samples were batched and stored at -80°C 
before analysis.  
 
Study design 
In dogs with newly diagnosed PH (group 1, n=11), PRA was measured before 
treatment. Subsequently, in 8 of these dogs, follow-up PRA measurements were 
obtained at different time points during hormone replacement therapy (n=37). The 
results in these 8 dogs later were included in the calculations for Figures 3 and 4. 
In dogs with diseases mimicking PH (group 2, n=10), PRA was measured once at 
initial presentation.  
In healthy dogs (group 3, n=21), PRA was measured before and 2 hours after 
feeding. 
In dogs with previously diagnosed PH and included in the study during ongoing 
hormone replacement therapy (group 4, n=17), PRA was measured once (5 dogs) or 
 11 
repeatedly at 1- to 6-months interval (12 dogs) for a total of 72 plasma samples. The 
results in these 17 dogs later were included in the calculations for Figures 3 and 4. 
  
Treatments 
Mineralocorticoid replacement therapy of confirmed PH consisted of fludrocortisone 
acetate (FC) or desoxycorticosterone pivalate (DOCP). The starting dosage of 
fludrocortisone acetatec was 0.01-0.02 mg/kg/d PO divided twice daily. Efficacy of FC 
treatment was assessed regularly by monitoring clinical signs, renal function (BUN 
and serum creatinine concentration) and serum electrolyte concentrations (sodium, 
potassium, phosphorus). The FC dosage was adjusted mainly according to the 
serum potassium concentration. Dose adjustments were made in increments of 
0.025-0.1 mg/dog depending on the size of the dog. The starting dosage and starting 
injection interval of DOCPd was 2 mg/kg SC q25 days. Depending on electrolyte 
concentrations 14 days after injection, the DOCP dosage was adjusted. In the event 
of normal serum electrolyte concentrations, the DOCP dose was slightly decreased 
(5-10 %) at the next injection. In the case of normal serum electrolyte concentrations 
at the time of the next injection, the injection interval was increased stepwise by 1 
day.  
Seven of the dogs with newly diagnosed PH were started on FC therapy and 4 of 
them on DOCP therapy. Two of the dogs started on FC therapy were later changed 
to DOCP therapy. 
Fifteen of the dogs with previously treated PH were on FC therapy and 2 on DOCP 
therapy at the time of their inclusion in the study. Three dogs treated with FC later 
were changed to DOCP therapy.   
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All dogs also were treated with glucocorticoids. The following standardized protocol 
was used for guiding glucocorticoid therapy: starting dosage of 2 mg/kg prednisolone 
IV after the ACTH stimulation test; then, 1 mg/kg prednisolone IV q6h during the first 
24 hours. If the dogs seemed stable after 24 hours, the glucocorticoid dosage was 
decreased to 0.5 mg/kg prednisolone IV q12h. Prednisolone therapy was changed to 
PO as soon as the dogs ate and vomiting had stopped. At the time of discharge, the 
prednisolone dosage was decreased to 0.5 mg/kg PO q24h. Additional glucocorticoid 
reduction was individualized based on clinical signs (e.g., appetite, activity level, 
diarrhea, vomiting, polyuria, polydipsia, weight gain) and on the assessment of the 
clinician. In general, the goal was to reach a glucocorticoid dosage of no more than 
0.1-0.2 mg/kg PO q 24h. In dogs with signs of glucocorticoid over dosage (e.g., 
polyuria, polydipsia, weight gain), glucocorticoid therapy was decreased further and 
in dogs treated with FC stopped if possible.  
 
Statistical analysis 
Statistical analysis was performed with commercial software using non-parametric 
tests.e,f Data are expressed as median and range. Differences in PRA before or after 
feeding were tested by using the Wilcoxon signed rank test. Differences in PRA 
among groups were tested by using the Kruskal Wallis H test and Dunn’s post-test. 
Changes in PRA during therapy were tested by Friedman’s repeated measures test 
and Dunn’s post-test. Differences in PRA as well as in sodium and potassium 
concentrations between dogs on FC and DOCP therapy were tested by the Mann-
Whitney test. For dogs with repeated measurements, mean PRA, and serum sodium 
and potassium concentrations during FC or DOCP therapy were determined and 
analyzed statistically. Differences in the numbers of dogs with normal or abnormal 
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electrolyte concentrations between the 2 treatment groups were tested by the 
Fisher’s exact test. Linear correlation between PRA and serum sodium and 
potassium concentrations was calculated by Spearman non-parametric correlation. 
As above, for dogs with repeated measurements, mean PRA, and serum sodium and 
potassium concentrations during FC or DOCP therapy were analyzed.  The level of 
significance was set at p < 0.05. 
 
Results 
Animals 
Group 1: in the dogs with newly diagnosed PH, the age range was 1 to 10 years 
(median, 5 years) and the body weight ranged from 1.9 to 28.8 kg (median, 8.5 kg). 
There were 5 males (2 castrated) and 6 females (5 spayed). Nine purebred dogs and 
2 mixed-breed dogs were included. No breed was overrepresented.  
Group 2: in the dogs with diseases mimicking PH, the age range was 1 to 13 years 
(median, 3.5 years) and the body weight ranged from 6.7 to 42 kg (median, 19.9 kg). 
There were 5 males (3 castrated) and 5 females (3 spayed). Eight purebred dogs 
and 2 mixed-breed dogs were included. The final diagnoses were acute 
gastroenteritis (2), food-responsive enteropathy (2), inflammatory bowel disease (1), 
gastric ulceration (1), idiopathic megaesophagus (1), hypothyroidism (1), primary 
hyperparathyroidism (1) dirofilariasis and leishmaniasis (1). 
Group 3: in the healthy dogs, the age range was 1 to 12 years (median, 4 years) and 
the body weight ranged from 5 to 35 kg (median, 22 kg). There were 8 males (2 
castrated) and 13 females (11 spayed). Sixteen purebred dogs and 5 mixed-breed 
dogs were included.  
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Group 4: in the dogs with already treated PH, the age range was 1 to 14 years 
(median, 8 years) and the body weight ranged from 3.6 to 34 kg (median, 10.6 kg). 
There were 7 males (4 castrated) and 10 females (9 spayed). Eleven purebred dogs 
and 6 mixed-breed dogs were included. No breed was overrepresented.  
 
PRA in healthy dogs 
There was no influence of feeding on PRA in healthy dogs (p=0.44). Fasted PRA in 
healthy dogs ranged from 0.1 to 1.3 ng/ml/h (median, 0.6 ng/ml/h) and postprandial 
PRA ranged from 0.1 to 1.7 ng/ml/h (median, 0.75 ng/ml/h). The 5 and 95% 
percentiles of fasted PRA were 0.1 and 1.3 and those of postprandial PRA were 0.1 
and 1.7 ng/ml/h, respectively.  
 
Comparison of PRA in dogs with newly diagnosed PH, dogs with diseases mimicking 
PH and healthy dogs 
PRA before treatment was significantly higher in dogs with PH (2.9 to 89 ng/ml/h; 
median, 27 ng/ml/h) than in dogs with diseases mimicking PH (0.5 to 2.8 ng/ml/h; 
median, 1.0 ng/ml/h; p<0.001) and in healthy dogs (0.1 to 1.7 ng/ml/h; median, 0.8 
ng/ml/h; p<0.0001; Figure 1). PRA did not differ significantly between dogs with 
diseases mimicking PH and healthy dogs (p=0.13).  
 
PRA in dogs with PH before and after initiation of mineralocorticoid therapy 
PRA decreased significantly after the start of mineralocorticoid therapy (p=0.04; 
Figure 2A). However, the PRA response was different for the 2 treatments: PRA of 
dogs treated with FC remained very high and was unchanged. In contrast, in dogs 
treated with DOCP, PRA decreased into the normal range and even lower during 
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therapy (Figure 2B). Comparison of the treatment groups at each follow-up 
evaluation was not possible because of the low numbers of dogs.  
 
PRA and correlation with serum sodium or potassium concentrations 
There was a significant, negative correlation of PRA and sodium concentrations (r=-
0.74, p<0.0001) and a significant positive correlation of PRA and potassium 
concentrations (r=0.71, p<0.0001) in dogs with PH (groups 1 and 4) before and 
during therapy. 
 
PRA and serum electrolyte concentrations in dogs with PH already treated for PH 
For these calculations, 8 dogs from group 1 (4 on FC and 4 on DOCP therapy) and 
17 dogs from group 4 (15 on FC and 2 on DOCP therapy) were used. In 2 dogs of 
group 1 and in 3 dogs of group 4, mineralocorticoid therapy was changed from FC to 
DOCP during the study, leading to 2 and 3 additional results in the DOCP group. 
Therefore, a total of 19 results (4 from group 1 and 15 from group 4) in the FC group 
and 11 results (6 from group 1 and 5 from group 4) in the DOCP group were 
included.   
PRA was significantly lower in dogs on DOCP therapy (0.04-6.13 ng/ml/h; median, 
0.04 ng/ml/h) than in dogs on FC therapy (8.7-47.5 ng/ml/h; median, 16.8 ng/ml/h; 
p<0.0001; Figure 3).  
Serum sodium concentrations of dogs treated with DOCP were significantly higher 
(154-158 mmol/l; median, 156 mmol/l) than those of dogs treated with FC (138-155 
mmol/l; median, 147 mmol/l; p<0.0001; Figure 4A). Serum potassium concentrations 
of dogs treated with DOCP were significantly lower (4.3-5.1 mmol/l; median, 4.6 
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mmol/l) than those of dogs treated with FC (5.1-6.3 mmol/l; median, 5.4 mmol/l; 
p<0.0001; Figure 4B). 
Significantly more dogs treated with DOCP had serum sodium (p<0.0001) or 
potassium (p<0.0001) concentrations within the normal range than did dogs treated 
with FC.  
 
Change in mineralocorticoid therapy 
Five dogs were changed from FC to DOCP therapy due to adverse glucocorticoid 
effects, lack of normalization of serum electrolyte concentrations or both. The FC 
dosage and the prednisolone dosage at the time of treatment change ranged from 
0.013 to 0.026 mg/kg/d (median, 0.017 mg/kg/d) divided q12h and from 0 to 0.2 
mg/kg/d (median, 0.06 mg/kg/d), respectively.  
In 4 of the dogs, follow-up samples on either FC or DOCP treatment could be 
obtained. The PRA and serum sodium and potassium concentrations in the 4 dogs 
on FC ranged from 2.8 to 37 ng/ml/h (median, 17 ng/ml/h), 135 to 156 mmol/l 
(median, 146 mmol/l) and 4.2 to 7.1 mmol/l (median, 5.6 mmol/l), respectively. After 
changing to DOCP therapy, PRA and serum sodium and potassium concentrations in 
the 4 dogs ranged from 0.03 to 2.2 ng/ml/h (median, 0.12 ng/ml/h), 151 to 160 mmol/l 
(median, 156 mmol/l) and 4.2 to 5.3 mmol/l (median, 4.6 mmol/l), respectively (Figure 
5A-C).  
 
Discussion    
Dogs with PH have higher PRA than do healthy dogs. These results confirm previous 
observations.1 Renal renin secretion apparently is enhanced in an attempt to try and 
further stimulate adrenal mineralocorticoid secretion, which is lacking in PH. In 
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contrast, PRA was not increased in dogs with diseases mimicking PH. Dogs with 
diseases mimicking PH were included because of clinical signs or laboratory findings 
commonly seen in dogs with PH (e.g., gastrointestinal illness, hyponatremia, 
hyperkalemia). Many of these dogs presented with decreased plasma volume (e.g., 
signs of dehydration, low blood pressure or both) and were classified as being 
critically ill. Thus, they would have been expected to have high PRA. Possibly, in 
contrast to true PH, fluid therapy at the time of PRA sampling may already have 
corrected factors (e.g. volume depletion) that would have stimulated renin secretion 
in dogs with diseases mimicking PH. Alternatively, hepatic or renal insufficiency may 
have prevented an increase in PRA.  
PRA in dogs with PH decreased during mineralocorticoid therapy. This observation is 
similar to the situation in humans with PH, in whom PRA is increased before therapy 
and decreases during therapy.10 In human medicine, PRA is the most sensitive 
marker for identifying insufficient or excessive mineralocorticoid replacement 
therapy.10 For optimal treatment control of PH, PRA should be within the normal 
range of healthy humans.10 Our results confirm that, in dogs, reference PRA results 
are very similar to those of humans when individuals with or without PH are 
compared.1,10,13 In addition, PRA of healthy dogs and dogs with PH on successful 
treatment were very similar to those results in healthy humans.1,10,13 We therefore 
hypothesize that PRA can be used to titrate mineralocorticoid therapy in dogs as well 
as in humans. Interestingly, based on our PRA results, SC DOCP treatment seemed 
to be more effective than PO FC therapy. This observation was confirmed by serum 
sodium and potassium concentrations and also by clinical observations (data not 
shown). More dogs treated with DOCP had normal serum sodium and potassium 
serum concentrations when compared to dogs treated with FC. PRA of dogs treated 
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with FC was higher than PRA of dogs treated with DOCP. Moreover, in the dogs that 
were changed from FC to DOCP therapy, pathologically increased PRA and serum 
potassium concentrations and pathologically decreased serum sodium 
concentrations observed during FC therapy were normalized after changing to DOCP 
therapy. Our findings suggest that DOCP lowers PRA and normalizes serum 
electrolyte concentrations in a more predictable way than does FC. Possible 
explanations for a lesser effect of FC therapy in dogs could be decreased absorption 
of FC from the gastrointestinal tract, lower mineralocorticoid activity of FC compared 
to DOCP or decreased owner compliance with orally administered medication. 
Certainly, owner compliance could have influenced treatment control in some dogs 
on FC. However, owners of dogs with PH understood that they were treating with a 
life-threatening disease in their dogs, and thus poor owner compliance seems an 
unlikely explanation. In humans, the mineralocorticoid replacement therapy of choice 
in patients with PH is PO FC. Normalization of serum sodium and potassium 
concentrations and of PRA seems very consistent during therapy.10 It is evident 
however that serum sodium and potassium concentrations require a smaller FC 
dosage for normalization than does PRA.10 The FC dosage leading to PRA in the 
desired range shows considerable interindividual variability.10,15 The primary problem 
of FC therapy in dogs is the risk of adverse glucocorticoid effects. In some dogs 
adverse glucocorticoid effects seem to occur before an FC dosage adequate for 
normalization of serum electrolyte concentrations and PRA can be achieved. 
Possibly, dogs are more sensitive to adverse glucocorticoid effects or FC may have 
higher glucocorticoid activity or lower mineralocorticoid activity in dogs than in 
humans.   
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In the only larger study3 comparing FC and DOCP treatment in dogs, no difference 
was seen between FC and DOCP with regard to control of serum electrolyte 
concentrations and survival time. However, the authors reported that 14% of dogs 
with PH that initially were treated with FC had to be changed to DOCP because of 
adverse effects, poor response to therapy, owner convenience, or financial 
considerations.3 In this study as well as in our study, no dog had to be changed from 
DOCP to FC. Several other authors reported that an inadequate mineralocorticoid 
dosage was more commonly seen with FC than with DOCP.4,5  
In all of our dogs treated with DOCP, PRA was completely suppressed, which in 
human medicine indicates excessive treatment with mineralocorticoids.10 This 
observation is in agreement with the clinical experience of several authors that most 
dogs are well controlled with lower doses of DOCP.3,16,17 In 1 study, only 18.2 % of 
dogs required the recommended dosage of 2.2 mg/kg.3 In a recent study, no 
significant differences in survival time or serum electrolyte concentrations were seen 
in dogs treated with different dosages of DOCP (0.4-3.8 mg/kg).17 The authors 
concluded that initial DOCP dosages < 2.2 mg/kg may be effective in controlling 
serum electrolyte concentrations in dogs with PH without adversely affecting 
survival.17 Our finding of completely suppressed PRA in dogs on DOCP further 
substantiates this hypothesis. We hypothesize that it would be possible to decrease 
DOCP dosage until PRA is detectable while serum electrolytes concentrations are 
still normal. This would allow calibrations of mineralocorticoid therapy. In the dogs in 
which we decreased the DOCP dosage, PRA still was completely suppressed except 
in 1 case. In human medicine, one problem of mineralocorticoid overdosage is the 
risk of iatrogenic hypertension and potential long-term complications.17,18 In dogs 
treated with 2.2 mg/kg DOCP every 30 days for 3 months there was no effect on 
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blood pressure.19 However, when overdosed up to 15-fold over a period of 6 months, 
dogs developed polyuria, polydipsia, decreased serum potassium concentrations and 
increased serum sodium concentrations.20 These findings clearly indicate the need 
for additional dosing studies for the long-term management of dogs with PH using 
DOCP.  
In most dogs treated with FC, PRA remained increased. The renin-angiotensin 
system is integral in the maintenance of cardiovascular homeostasis. Increased renin 
activity leads to enhanced production of angiotensin I and angiotensin II. 
Angiotensins have important effects on vascular endothelium and vascular smooth 
muscle (e.g., vasoconstriction, vascular smooth muscle cell proliferation, 
atherosclerosis).21 In humans, PRA (or more precisely angiotensin II) is a well known 
cardiovascular risk factor.22-25 Strokes and myocardial infarctions are more frequent 
in patients with increased PRA. Effects of increased PRA and the enhanced growth 
effects of angiotensin II on the cardiovascular system and other cell systems in 
patients with PH are likely and await further investigation.  
In view of these observations, we prefer to start dogs with PH on DOCP instead of 
FC. We follow an approach similar to that suggested by Klein and Peterson and 
adjust the dosage individually as described above.26  
We acknowledge that measurement of PRA is not widely available for the 
management of dogs with PH, mostly because the method is not commonly available 
and blood sampling as described above is not possible for most practitioners. 
Measuring renin with an immunoassay could be considered as an alternative. The 
advantage of this method is an easier sampling procedure. In human medicine, renin 
concentrations correlate with PRA in healthy humans and patients with hypertension, 
but not in patients with other conditions.27,28  So far, no information about the 
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correlation of PRA and renin concentrations in dogs with different diseases is 
available. Renin concentrations in dogs would have to be measured indirectly (i.e. 
generation of angiotensin in the presence of added excess angiotensinogen), 
because no specific antibody for dog renin is commercially available.  
We conclude that measurement of PRA is a promising tool for establishing dosage 
and monitoring mineralocorticoid therapy in dogs with PH. Based on our results, 
DOCP treatment more effectively suppresses PRA compared to FC therapy and 
therefore is the preferred mineralocorticoid treatment in dogs.  
Footnotes 
aSynacthen®, Novartis Pharma Schweiz AG, Bern, Switzerland  
(During this study 250 µg ACTH/dog were used for the ACTH stimulation test. Today 
the authors use only 5 µg/kg ACTH for the ACTH stimulation test) 
bDPC Immulite®  1000, Siemens Schweiz AG, Zurich, Switzerland  
cFlorinef®, Bristol-Myers Squibb SA, 6340 Baar, Switzerland 
dPercorten®-V, Novartis Animal Health US, Greensboro, NC, USA 
eGraphPad Prism5, GraphPad Software, San Diego, CA, USA 
fSPSS 18.0 for Windows, SPSS Inc, Chicago, IL, USA 
eMartin LG, Behrend EN, Kemppainen RJ, Lee HJ. Basal aldosterone concentrations 
and response to ACTH stimulation in healthy and critically ill dogs. Abstract at the 
ACVIM Forum 2012, New Orleans, Louisiana, USA 
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Figure legends:  
Figure 1:  
Plasma renin activity (PRA) of dogs with primary hypoadrenocorticism (PH, n=11), 
dogs with diseases mimicking PH (n=10) and healthy dogs (n=21). The horizontal 
bars represent the medians of each group.  
 
Figure 2:  
A: Plasma renin activity (PRA) of dogs with primary hypoadrenocorticism (PH) 
treated with fludrocortisone acetate (FC, open circles) or with desoxycorticosterone 
pivalate (DOCP, closed circles). Three dogs were lost to follow-up (triangles).  
B: Bar graphs showing mean (SD) plasma renin activity (PRA) of dogs with PH 
treated with FC (white bars) and DOCP (black bars).  
 
Figure 3:  
Plasma renin activity (PRA) of dogs with primary hypoadrenocorticism on 
fludrocortisone acetate therapy (FC, n=19) and on desoxycorticosterone pivalate 
therapy (DOCP, n=11). The horizontal bars represent the medians.  
 
Figure 4:  
Serum sodium (A) and potassium (B) concentrations of dogs with primary 
hypoadrenocorticism on fludrocortisone acetate therapy (FC, n=19) and on 
desoxycorticosterone pivalate therapy (DOCP, n=11). The horizontal bars represent 
the medians.  
 
Figure 5:  
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Effects of switching hormone replacement therapy in four dogs with primary 
hypoadrenocorticism (square, triangle, rhombus, and circle) from fludrocortisone 
acetate (FC, open symbols) to desoxycorticosterone pivalate (DOCP, closed 
symbols). 
Plasma renin activity (A), serum sodium concentrations (B) and serum potassium 
concentrations (C): All normalize after switching from initial FC to final DOCP 
therapy. The dotted lines in figures A and C represent the upper limit of normal 
values. The dotted line in figure B represents the lower limit of normal values.  
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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